ProShares Ultra NASDAQ Biotechnology
BIB
BIB
38 hedge funds and large institutions have $23.3M invested in ProShares Ultra NASDAQ Biotechnology in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
62% less call options, than puts
Call options by funds: $8.07M | Put options by funds: $21.4M
Holders
38
Holding in Top 10
1
Calls
$8.07M
Puts
$21.4M
Top Buyers
| 1 | +$1.73M | |
| 2 | +$858K | |
| 3 | +$759K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$714K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$603K |
Top Sellers
| 1 | -$5.37M | |
| 2 | -$551K | |
| 3 | -$423K | |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$316K |
| 5 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
-$272K |